Clinical utility of a glycosylated fibronectin test (Lumella <sup>TM</sup> ) for assessment of impending preeclampsia
The ability to use this test in a POC format provides a method for practitioners to quickly determine risk for preeclampsia in their pregnant patients and offers an affordable alternative, as a single analyte to other diagnostic or screening tests that require laboratory-based testing or ultrasound equipment. Independent of preeclampsia, an elevated GlyFn was also correlated with preterm delivery and requires further study.
Authors
- Mirosław Wielgoś (ORCID: https://orcid.org/0000-0003-2581-3668)
- Maurizio Arduini
- Jan Stener Jørgensen (ORCID: https://orcid.org/0000-0001-5222-2535)
- Lina Gao (ORCID: https://orcid.org/0000-0001-9382-0419)
- Marián Kacerovský (ORCID: https://orcid.org/0000-0001-9858-7900)
- Paweł Jan Stanirowski (ORCID: https://orcid.org/0000-0001-7445-7546)
- Alizée Froeliger (ORCID: https://orcid.org/0000-0002-7145-8874)
- Gian Carlo Di Renzo
- José Luis Bartha
- Michael G. Gravett
Institutions
- Oregon National Primate Research Center (US)
- Université de Bordeaux (FR)
- Oregon Health & Science University (US)
- University of Southern Denmark (DK)
- Sechenov University (RU)
- University of Washington (US)
- Medical University of Warsaw (PL)
- European School of Molecular Medicine (IT)
- Ospedale Santa Maria (IT)
- Ministry of Interior and Administration (PL)
- University Hospital Hradec Králové (CZ)
- Universidad Autónoma de Madrid (ES)
- Misericordia University (US)
Publication Details
- Journal
- The Journal of Maternal-Fetal & Neonatal Medicine
- Published
- 2025-03-07
- DOI
- https://doi.org/10.1080/14767058.2025.2474674
- Citations
- 2
- Primary Topic
- Pregnancy and preeclampsia studies
- Type
- article
- Field-Weighted Citation Impact
- 4.11